Compare Moderna, Inc. (MRNA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Moderna, Inc. trades at $137.25 (market cap $56.02B), while Vanguard Total International Stock Index Fund ETF trades at $87.61. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | VXUS | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Sector/Thematic |
52-Week High | $174.38 | $88.41 |
52-Week Low | $22.36 | $72.17 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
VXUS trades at $88.08, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers broad international stock exposure, excluding U.S. equities, with a low expense ratio of 0.06% as of Vanguard's latest disclosure in 2026. Recent news highlights institutional buying and long-term growth potential amid U.S. market concentration concerns.
Outlook is positive for diversification benefits and valuation discounts relative to U.S. stocks, supported by analyst optimism. Risks include foreign tax credit limitations in IRAs and emerging market volatility. Wall Street sentiment leans bullish due to improved global growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
